Income statement
CAD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 2M | 4M | 4M | 1M | 925K |
| Gross Profit | -1M | -3M | 3M | 2M | 467K |
| Operating Income | -3M | -6M | 205K | -5M | -2M |
| EBITDA | -2M | -5M | 1M | -12M | -2M |
| Net Income | -3M | -6M | -162K | -13M | -12M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
THC Biomed Intl Ltd. (THCBF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -35.1%, EPS growth of +51.9%, a dividend yield of 0.0%. What stands out right now is revenue -35.1%, EPS +51.9%, free cash flow -43.8% with operating margin -95.9% and ROIC -28.0%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines THCBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
THCBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
THCBF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for THCBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$925.3K
-37.9% YoY
FY Net Income
-$12.5M
+1.9% YoY
Free Cash Flow
-$7.6M
+16.2% YoY
Revenue Growth
-35.1%
EPS Growth
+51.9%
Gross Margin
-30.8%
Net Margin
-91.8%
Income statement
CAD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 2M | 4M | 4M | 1M | 925K |
| Gross Profit | -1M | -3M | 3M | 2M | 467K |
| Operating Income | -3M | -6M | 205K | -5M | -2M |
| EBITDA | -2M | -5M | 1M | -12M | -2M |
| Net Income | -3M | -6M | -162K | -13M | -12M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 484K | 111K | 751K | 991K | 2M |
| Total Assets | 15M | 17M | 22M | 18M | 14M |
| Total Liabilities | 8M | 8M | 7M | 5M | 2M |
| Shareholder Equity | 7M | 10M | 15M | 13M | 12M |
| Total Debt | 2M | 3M | 3M | 3M | 2M |
| Net Debt | 1M | 3M | 2M | 2M | -392K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-30.3% YoY
Capital Expenditures
5M
+28.3% YoY
Free Cash Flow
8M
+16.2% YoY
Key ratios
Gross Margin
-30.8%
Operating Margin
-95.9%
Net Margin
-91.8%
ROE
-36.7%
Debt / Equity
0.65x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.